Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage drug development company focused on novel oral therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD). The BLTE news feed highlights how the company advances its lead candidate, Tinlarebant, through late-stage clinical trials and global regulatory pathways.
Investors and observers following Belite Bio’s news can track updates on pivotal clinical programs such as the Phase 3 DRAGON and DRAGON II trials in adolescent STGD1 patients and the Phase 3 PHOENIX trial in GA. Company announcements cover milestones like completion of trial enrollment, last subject visits, and the release of topline efficacy and safety data, including the reported positive Phase 3 DRAGON results showing reduced lesion growth in STGD1.
The BLTE news stream also features information on regulatory interactions and designations for Tinlarebant, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, Orphan Drug, and Sakigake (Pioneer Drug) designations, as well as decisions by agencies such as China’s NMPA and the UK’s MHRA to accept applications based on interim Phase 3 data. In addition, readers can follow Belite Bio’s capital markets activities, including registered direct offerings, private placements, and underwritten public offerings of American Depositary Shares that the company describes as supporting clinical development and commercialization preparation.
By reviewing Belite Bio news, users can see how clinical data, regulatory developments, and financing events shape the company’s efforts to develop Tinlarebant as a potential oral treatment option for inherited and degenerative retinal diseases.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
The event will take place in Miami, FL from March 10-12, 2025. The company's executive management team will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.
Investors and interested parties can access the webcast through the 'Events' section on Belite Bio's investor relations website. The presentation recording will remain available for 90 days after the event.
Belite Bio (NASDAQ: BLTE) announced interim analysis results from its pivotal Phase 3 DRAGON trial of Tinlarebant in adolescent Stargardt disease patients. The Data Safety Monitoring Board (DSMB) recommended trial continuation without modifications, maintaining the original 104-subject sample size. The trial is expected to complete by Q4 2025.
Key findings show that Tinlarebant is well-tolerated with a consistent safety profile. Visual acuity remained stable in most subjects, with mean changes from baseline of less than three letter scores under both standard and low luminance throughout the two-year study.
The DRAGON trial is a randomized, double-masked, placebo-controlled study across 11 jurisdictions, with 2:1 randomization (active:placebo). The primary endpoint measures atrophic lesion growth rate. Tinlarebant has received multiple regulatory designations, including Fast Track and Rare Pediatric Disease in the U.S., Orphan Drug status in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for Stargardt disease, which currently has no approved treatments.
Belite Bio (BLTE) has announced a registered direct offering expected to raise $15 million through the sale of 258,309 American Depositary Shares (ADSs) and warrants. The offering price is set at $58.07 per ADS and accompanying warrant, matching the day's closing price. The five-year warrants could potentially generate an additional $15 million if exercised.
The offering, conducted under a shelf registration statement, is expected to close around February 7, 2025. Titan Partners Group, a division of American Capital Partners, serves as the sole placement agent. The company plans to use the proceeds for working capital and general corporate purposes.
Belite Bio (NASDAQ: BLTE) reported Q3 2024 financial results and clinical progress. The company has dosed the first patient in Phase 2/3 DRAGON II trial for Stargardt disease treatment and enrolled over 280 subjects in the Phase 3 PHOENIX trial for geographic atrophy. Cash position stands at $109.0 million, with Q3 net loss of $8.7 million. R&D expenses decreased to $6.8 million from $8.7 million year-over-year. The company appointed Dr. Hendrik Scholl as CMO and received $28.75 million from warrant exercises. An interim analysis from the Phase 3 DRAGON trial is expected by end of 2024 or early 2025.
Belite Bio (NASDAQ: BLTE) announced it will host a webcast on November 12, 2024 at 4:30 p.m. Eastern Time to discuss its third quarter 2024 financial results and provide a business update. The clinical-stage biopharmaceutical company, which focuses on developing novel therapeutics for degenerative retinal diseases, will make the webcast available through their website. A replay will be accessible for approximately 90 days following the event.
Belite Bio (NASDAQ: BLTE) has secured US$28.75 million through the exercise of warrants at US$44.14 per share for 651,380 ordinary shares. In exchange for this immediate cash exercise, the company will issue new unregistered warrants for the same number of shares with an exercise price of US$70.00 per share, valid for five years. If these new warrants are fully exercised, they could generate additional gross proceeds of approximately US$45.6 million. The company plans to use the proceeds for general corporate purposes.
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the American Academy of Ophthalmology Annual Meeting (AAO 2024) from October 18-21, 2024, in Chicago. The company will present data from its completed Phase II adolescent Stargardt disease trial.
Two presentations are scheduled:
- A podium presentation titled "Tinlarebant (LBS-008) for Adolescents with Stargardt Disease" by Dr. Quan Dong Nguyen on October 19, 2024, at 10:33 AM CDT.
- An e-poster presentation titled "Investigation of an Oral Retinol Binding Protein 4 Antagonist in the Treatment of Childhood-onset Stargardt Disease" by Dr. Nathan L Mata, available on-demand.
These presentations will showcase Belite Bio's progress in developing novel therapeutics for Stargardt disease, a degenerative retinal condition with significant unmet medical needs.
Belite Bio, a clinical-stage biopharmaceutical company (NASDAQ: BLTE) focusing on novel therapeutics for degenerative retinal diseases, has announced its participation in the Maxim Group 2024 Healthcare Virtual Summit. Dr. Hendrik P.N. Scholl, the company's Chief Medical Officer, will be part of the 'Ocular Drug Development' panel discussion.
The event is scheduled for Tuesday, October 15, 2024, at 11:00 am ET. Interested parties can access the live panel discussion through Maxim's M-Vest website. For registration and additional information, visitors are directed to https://m-vest.com/events/healthcare-10152024.
This participation underscores Belite Bio's commitment to advancing treatments for unmet medical needs in the field of degenerative retinal diseases.
Belite Bio (NASDAQ: BLTE) has dosed the first patient in the Phase 2/3 DRAGON II trial of Tinlarebant for Stargardt Disease (STGD1) treatment. The trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in about 60 adolescent STGD1 subjects across the U.S., U.K., and Japan. Tinlarebant, an oral therapy designed to reduce vitamin A-based toxin accumulation causing retinal disease, has received Orphan Drug and Sakigake Designation in Japan. The trial follows a completed Phase 1b study in Japan and is part of Belite's efforts to address unmet needs in STGD1 treatment. Simultaneously, Belite's Phase 3 PHOENIX trial for Tinlarebant in Geographic Atrophy (GA) is ongoing with over 200 subjects enrolled.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in three upcoming investor conferences. The executive management team will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024, at 9:30 am ET for a fireside chat.
2. 2024 Cantor Global Healthcare Conference in New York on September 18, 2024, at 3:40 pm ET for a corporate presentation.
3. Deutsche Bank Depositary Receipts Virtual Investor Conference on September 25, 2024, at 11:00 am ET for a virtual corporate presentation.
Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days after each event.